85%Confidence
0Views
FDASource
2026-04-21Date
Summary
Teva's second clonidine patch recall for similar CGMP deviations points to recurring quality control lapses at its manufacturing partner. This could lead to regulatory penalties and damage Teva's reputation in the generic transdermal market.
Actionable: Investigate the financial and operational implications for Teva, including potential fines and costs associated with resolving manufacturing issues.
AI Confidence: 85%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionWithin U.S
productClonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx Only, Manufactured by: Actavis Laboratories
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now